Evidence map›Paper›PMID 24657568›Full record

ArticleEuropean journal of medicinal chemistry2014

Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: structure-activity relationships and potent antileukemic and antilymphoma cytotoxicity.

Yahaira Santiago-Vazquez, Swagatika Das, Umashankar Das, Elisa Robles-Escajeda, Nora M Ortega, Carolina Lema, Armando Varela-Ramírez, Renato J Aguilera, Jan Balzarini, Erik De Clercq and 3 more

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Synthetic Cyclic CAntioxidants (Basel, Switzerland) · 2026
    Article
  2. Novel cyclic CCancer cell international · 2025
    Article
  3. Article
  4. A virus changed my life.Molecular biology of the cell · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yahaira Santiago-VazquezCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Swagatika DasDrug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada.
Umashankar DasDrug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5C9, Canada. Electronic address: umashankar.das@usask.ca.
Elisa Robles-EscajedaCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Nora M OrtegaCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Carolina LemaCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Armando Varela-RamírezCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Renato J AguileraCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA. Electronic address: raguilera@utep.edu.
Jan BalzariniRega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium.
Erik De ClercqRega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium.
Stephen G DimmockDepartment of Finance, Nanyang Technological University, Singapore 639798, Singapore.
Dennis K J GoreckiCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.
Jonathan R DimmockCytometry, Screening and Imaging Facility, Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968-0519, USA.

Funding

TOXICOLOGY PROJECTG12RR008124 · NCRR · UNIVERSITY OF TEXAS EL PASO · PI WALSH, ELIZABETH J · 1992 to 2011
$20.8M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
MARC U*STAR Program at the University of California, Los AngelesT34GM008563 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCEVOY, MEGAN M, POE, GINA R · 1996 to 2023
$9.7M
Characterization of novel compounds with anti-lymphoma activitySC3GM103713 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2013 to 2016
$453k
NCRR NIH HHS G12 RR008124NIGMS NIH HHS 5 R25 GM069621-10NIGMS NIH HHS ISC3GM10371NIGMS NIH HHS R25 GM069621NIGMS NIH HHS SC3 GM103713NIGMS NIH HHS T34 GM008563NIMHD NIH HHS 8G12MD007592NIMHD NIH HHS G12 MD007592
6 · The paper itself

Abstract

Novel clusters of 3,5-bis(benzylidene)-4-oxo-1-piperidinyl dimers 3-5 were evaluated against human Molt4/C8 and CEM T-lymphocytes and human HeLa cervix adenocarcinoma cells as well as murine L1210 leukemia neoplasms. Several of these compounds demonstrated IC50 values in the submicromolar and low micromolar range and compounds possessing 4-fluoro, 4-chloro and 3,4,5-trimethoxy substituents in the series 3 and 4 were identified as potent molecules. A heat map revealed the very high cytotoxic potencies of representative compounds against a number of additional leukemic and lymphoma cell lines and displayed greater toxicity to these cells than nonmalignant MCF10A and Hs-27 neoplasms. These dienones are more refractory to breast and prostate cancers. The evaluation of representative compounds in series 3-5 against a panel of human cancer cell lines revealed them to be potent cytotoxins with average IC50 values ranging from 0.05 to 8.51 μM. In particular, the most potent compound 4g demonstrated over 382-fold and 590-fold greater average cytotoxic potencies in this screen than the reference drugs, melphalan and 5-fluorouracil, respectively. A mode of action investigation of two representative compounds 3f and 4f indicated that they induce apoptosis which is due, at least in part, to the activation of caspase-3 and depolarization of the mitochondrial membrane potential.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationDimerizationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHeLa CellsHL-60 CellsHumansLeukemiaLymphomaMolecular StructurePiperidinesStructure-Activity RelationshipAntineoplastic AgentsPiperidines4-PiperidoneApoptosisCytotoxicityMitochondriaStructure–activity relationshipsUnsaturated ketones

Identifiers

PMID24657568
PMCPMC4215945

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.